Advertisement

Topics

Cowen $RVNC BUY PT 55 believe that this is confirming of the Revance thesis that there is indeed a viable market for longer-acting toxins. Given Revance's clinical data and stage of development, if this is the cause of any weakness, it should quickly reve

16:40 EDT 14 Sep 2018 | tgtxdough

Cowen BUY PT 55 believe that this is confirming of the Revance thesis that there is indeed a viable market for longer-acting toxins. Given Revance's clinical data and stage of development, if this is the cause of any weakness, it should quickly reverse. https://twitter.com/mikegoodma/status/1040624933741715462 …

Original Article: Cowen $RVNC BUY PT 55 believe that this is confirming of the Revance thesis that there is indeed a viable market for longer-acting toxins. Given Revance's clinical data and stage of development, if this is the cause of any weakness, it should quickly reve

NEXT ARTICLE

More From BioPortfolio on "Cowen $RVNC BUY PT 55 believe that this is confirming of the Revance thesis that there is indeed a viable market for longer-acting toxins. Given Revance's clinical data and stage of development, if this is the cause of any weakness, it should quickly reve"

Advertisement
Quick Search
Advertisement
Advertisement